Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
Leukemia ; 29(12): 2338-46, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26139427

ABSTRACT

We examined the combination of the mammalian target of rapamycin inhibitor everolimus with bortezomib and rituximab in patients with relapsed/refractory Waldenstrom macroglobulinemia (WM) in a phase I/II study. All patients received six cycles of the combination of everolimus/rituximab or everolimus/bortezomib/rituximab followed by maintenance with everolimus until progression. Forty-six patients were treated; 98% received prior rituximab and 57% received prior bortezomib. No dose-limiting toxicities were observed in the phase I. The most common treatment-related toxicities of all grades were fatigue (63%), anemia (54%), leucopenia (52%), neutropenia (48%) and diarrhea (43%). Thirty-six (78%) of the 46 patients received full dose therapy (FDT) of the three drugs. Of these 36, 2 (6%) had complete response (90% confidence interval (CI): 1-16). In all, 32/36 (89%) of patients experienced at least a minimal response (90% CI: 76-96%). The observed partial response or better response rate was 19/36 (53, 90 CI: 38-67%). For the 36 FDT patients, the median progression-free survival was 21 months (95% CI: 12-not estimable). In summary, this study demonstrates that the combination of everolimus, bortezomib and rituximab is well tolerated and achieved 89% response rate even in patients previously treated, making it a possible model of non-chemotherapeutic-based combination therapy in WM.


Subject(s)
Waldenstrom Macroglobulinemia/drug therapy , Aged , Aged, 80 and over , Bortezomib/administration & dosage , Bortezomib/adverse effects , Drug Therapy, Combination , Everolimus/administration & dosage , Everolimus/adverse effects , Female , Humans , Male , Middle Aged , Mutation , Myeloid Differentiation Factor 88/genetics , Receptors, CXCR4/genetics , Recurrence , Rituximab/administration & dosage , Rituximab/adverse effects
SELECTION OF CITATIONS
SEARCH DETAIL
...